Ny'kenzie Shatreese Nalls, ASSOCIATES DEGREE Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 107 Midway Drive, Winfield, AL 35594 Phone: 877-211-2882 Fax: 205-449-0049 |
News Archive
Exhale on a cold winter day and you will see the water vapor coming out of your mouth.
Phase I/II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK+ non-small cell lung cancer (NSCLC), with 58 of 78 ALK+ patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.
Conditions such as Parkinson's disease are a result of pathogenic changes to proteins. In the neurodegenerative condition of Parkinson's disease, which is currently incurable, the alpha-synuclein protein changes and becomes pathological. Until now, there have not been any antibodies that could help to demonstrate the change in alpha-synuclein associated with the disease. An international team of experts led by Gabor G. Kovacs from the Clinical Institute of Neurology at the MedUni Vienna has now discovered a new antibody that actually possesses this ability.
Royal Philips Electronics, in partnership with the American College of Cardiology, spotlight the growing need for minimally-invasive interventions to address a spectrum of cardiac conditions, such as structural and degenerative heart issues. The need to reduce invasive surgical interventions and complication rates is driving innovations in minimally invasive approaches.
A new study by researchers at Sanford Burnham Prebys Medical Discovery Institute, the National Cancer Institute, and the Chulabhorn Research Institute has found that blocking the activity of a key immune receptor, the lymphotoxin-beta receptor (LTβR), reduces the progression of liver cancer.
› Verified 9 days ago